Article Versions Notes

Wong K, Sheehan-Dare G, Nguyen A, Ho B, Liu V, Lee J, Brown L, Dear R, Chan L, Sharma S, et al. ⁶⁴Cu-SAR-Bombesin PET-CT Imaging in the Staging of Estrogen/Progesterone Receptor Positive, HER2 Negative Metastatic Breast Cancer Patients: Safety, Dosimetry and Feasibility in a Phase I Trial. Pharmaceuticals. 2022; 15(7):772. https://doi.org/10.3390/ph15070772

Wong, Keith, Gemma Sheehan-Dare, Andrew Nguyen, Bao Ho, Victor Liu, Jonathan Lee, Lauren Brown, Rachel Dear, Lyn Chan, Shikha Sharma, and et al. 2022. "⁶⁴Cu-SAR-Bombesin PET-CT Imaging in the Staging of Estrogen/Progesterone Receptor Positive, HER2 Negative Metastatic Breast Cancer Patients: Safety, Dosimetry and Feasibility in a Phase I Trial" Pharmaceuticals 15, no. 7: 772. https://doi.org/10.3390/ph15070772

Wong, K., Sheehan-Dare, G., Nguyen, A., Ho, B., Liu, V., Lee, J., Brown, L., Dear, R., Chan, L., Sharma, S., Malaroda, A., Smith, I., Lim, E., & Emmett, L. (2022). ⁶⁴Cu-SAR-Bombesin PET-CT Imaging in the Staging of Estrogen/Progesterone Receptor Positive, HER2 Negative Metastatic Breast Cancer Patients: Safety, Dosimetry and Feasibility in a Phase I Trial. Pharmaceuticals, 15(7), 772. https://doi.org/10.3390/ph15070772